Aspira Women'S Health INC. 8-K Filing
Ticker: AWHL · Form: 8-K · Filed: Dec 22, 2025 · CIK: 926617
Sentiment: neutral
Filing Stats: 597 words · 2 min read · ~2 pages · Grade level 13.9 · Accepted 2025-12-22 08:49:30
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 AWHL OTC QX Market Indicate by ch
Filing Documents
- awhl-20251216x8k.htm (8-K) — 36KB
- 0000926617-25-000010.txt ( ) — 144KB
- awhl-20251216.xsd (EX-101.SCH) — 3KB
- awhl-20251216_lab.xml (EX-101.LAB) — 16KB
- awhl-20251216_pre.xml (EX-101.PRE) — 10KB
- awhl-20251216x8k_htm.xml (XML) — 5KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On December 16, 2025, Aspira Women's Health Inc. ("Aspira") entered into a Laboratory Services Agreement (the "Agreement") with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories ("Mayo"). The Agreement is effective as of December 16, 2025. Under the Agreement, Aspira will provide certain reference laboratory testing services to Mayo, specifically the Ova1Plus (Ova1 and Overa) and OvaWatch tests, on a non-exclusive, as-requested basis for clinical purposes. The initial term of the Agreement is five years from the effective date, with automatic one-year renewal terms thereafter, subject to earlier termination by either party for convenience on at least ninety days' prior written notice, or earlier for cause. Mayo will list each Aspira test in Mayo's catalog and will be responsible for facilitating ordering and delivery of results, as well as billing for the applicable tests. Aspira will invoice Mayo for services performed in accordance with the Agreement, with fees remaining fixed during the initial term absent mutual agreement to adjust, subject to certain notice and review rights. The Agreement contains customary representations, covenants, and other provisions for arrangements of this type, including with respect to confidentiality, compliance with healthcare laws (including HIPAA), insurance, indemnification, non-exclusivity, and governing law. The Agreement is not filed herewith as Aspira is still finalizing appropriate redactions of certain information that is immaterial and the type of information that Aspira treats as private or confidential. Aspira will file the Agreement as soon as this process is complete.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Dated: December 22, 2025 ASPIRA WOMEN'S HEALTH INC. By: /s/ Brian Hungerford Name: Brian Hungerford Title: Chief Financial Officer